GFRA1 antibodies are biologics designed to bind specifically to the GFRA1 receptor, which is overexpressed in malignancies like breast cancer and osteosarcoma while showing limited expression in normal tissues . These antibodies are primarily investigated as components of antibody-drug conjugates (ADCs) for targeted cancer therapy, leveraging GFRA1’s rapid internalization properties for payload delivery .
Internalization Kinetics: Anti-GFRA1 antibodies (e.g., 10H9) exhibit rapid internalization, with >80% of target-positive cells internalizing the antibody within 30 minutes, enabling efficient delivery of cytotoxic payloads like pyrrolobenzodiazepine (PBD) dimers or monomethyl auristatin E (MMAE) .
Antigen Shedding: Soluble GFRA1 levels in patient serum range from 0.9–28 ng/ml, but this does not impede ADC efficacy in preclinical models .
Target Expression:
Efficacy:
Osteosarcoma: GFRA1 promotes cisplatin resistance via autophagy mediated by the SRC-AMPK pathway. Co-treatment with chloroquine (an autophagy inhibitor) and cisplatin reduced tumor volume in preclinical models .
Prognostic Marker: High GFRA1 expression correlates with lymph node metastasis, advanced disease stage, and poor survival in breast cancer .